ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition") today announced
that it has been awarded additional non-dilutive funding of
approximately $700,000 from the
Walloon Regional Government. Including this latest amount, Volition
has received approximately $3.7
million in non-dilutive funding from a number of local
agencies to date.
Dr. Gaetan Michel, Chief
Executive Officer of Volition's wholly-owned subsidiary, Belgian
Volition SPRL, commented, "We are grateful to the Walloon Region,
and in particular to the Vice-President of the Walloon Government
and Minister for Economy, Industry, Research, Innovation, Digital,
Employment and Training, Mr. Pierre-Yves Jeholet for his continued
support of the Company. We are committed to the region and plan to
recruit even more of the talented scientists in the area. This
funding will support our continued research and development
activities towards what we hope will be life-saving cancer
diagnostic tests."
Belgian Volition SPRL today also released a new video featuring
its Laboratory in Belgium
including interviews with team members. Click here to watch
the video filmed in June 2018.
Details About the Funding
Approximately $200,000 of this
funding is repayable with annual installments over 12 years
commencing in 2020. In addition to this, a percentage of Volition's
revenue may be payable over the same period.
About Volition
Volition is a multi-national life sciences company focused on
developing simple, easy to use, cost effective blood tests designed
to help diagnose a range of cancers. The tests are based on the
technology platform of Nucleosomics®, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. Volition's research and development
activities are currently centered in Belgium, with additional offices in
London, Texas and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
https://volitionrx.com/
or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter, LinkedIn,
Facebook, and YouTube are included in this document as inactive
textual references only.
Media/Investor Contacts
Louise Day, Chief Marketing &
Communications Officer
l.day@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice
President, Investor Relations
s.powell@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's bodily-fluid-based diagnostic
tests as well as Volition's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and Hypergenomics® and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners. Additionally, unless
otherwise specified, all references to "$" refer to the legal
currency of the United States of
America.
View original content with
multimedia:http://www.prnewswire.com/news-releases/volition-secures-additional-700-000-non-dilutive-funding-from-the-walloon-region-300675234.html
SOURCE VolitionRx Limited